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ing units (n 2) were diluted at least 4 fold to a ﬁnal volume of 400
mls. The median infused TNC was 2.13 x 107/kg with a TNC
recovery of 85% (range 50-105%) and a median trypan blue via-
bility of 89% (range 59-95%). While 6 patients had hypertension,
3 nausea and 1 chest tightness requiring intravenous therapy, no
patient suffered any severe adverse events associated with infusion.
The cumulative incidence of sustained donor neutrophil engraft-
ment was 100% in recipients of ablative regimens at a median of 26
days (range 14-33), and 89% in non-myeloablative recipients with
neutrophil recovery occurring at a median of 16 days (range 7-36).
The cumulative incidence of grades II-IV acute GVHD was 42%
at 100 days with no cases of grade IV acute GVHD, and 20% of
patients have chronic GVHD to date. In summary, we conclude
that this thaw technique is a valid alternative to UCB wash in adults
and larger children with cell dose yield and engraftment that
compare favorably to a traditional wash. This technique is faster,
more efﬁcient, reduces unit manipulation, speeds the time to pa-
tient infusion, and reduces the potential for loss of cells and may
therefore be the thaw technique of choice for adult UCBT.
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NONMYELOABLATIVE STEM CELL TRANSPLANTATION
Richard Champlin, M.D. MD Anderson Cancer Center
High dose myeloablative therapy with allogeneic hematopoietic
transplantation is an effective, yet risky treatment for hematologic
malignancies. There is a high risk of treatment related complica-
tions, ranging from 10 to 50% depending on histocompatibility,
age comorbidities and disease factors. The initial concept of allo-
geneic transplantation for treatment of cancer was to use the
transplant for supportive care, as a means to restore hematopoiesis
after myeloablative doses of chemotherapy and/or total body radi-
ation. The therapeutic beneﬁt of allogeneic marrow transplanta-
tion for many diagnoses is largely related to an associated immune-
mediated graft-vs.-malignancy effect. This realization has recently
led to development of less toxic, nonmyeloablative preparative
regimens to achieve engraftment and allow development of graft-
vs.-malignancy effects as a primary form of therapy. Engraftment is
favored by a high CD34 cell dose and histocompatiblity between
donor and recipient. More intensive immunosuppression is re-
quired to prevent rejection with greater genetic disparity. For cord
blood transplants, the preparative regimen must be sufﬁciently
immunosuppressive to prevent rejection of the cord blood graft,
involving a low cell dose and usually multiple HLA mismatches.
For nonmalignant disorders, it is not necessary to ablate diseased
tissues; it is only necessary to achieve mixed chimerism to provide
a source of normal hematopoietic cells. Results of nonablative stem
transplants will be reviewed for each hematologic malignancy. In
many diagnoses, it still appears necessary to induce marked cytore-
duction by the preparative regimen to achieve optimal results.
Strategies to augment graft-vs-malignancy immune effects are be-
ing studied to reduce the risk of disease relapse. Novel strategies
are under evaluation for separation of graft-vs-malignancy from
GVHD. Overall this strategy has been successful in reducing the
risks of treatment related mortality and making it a potentially
curative treatment option to older patients and those with comor-
bidities who where previously not eligible for allogeneic stem cell
transplantation.
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NONMYELOABLATIVE UMBILICAL CORD BLOOD TRANSPLANTATION
Claudio G. Brunstein, Todd DeFor and John E. Wagner Bone &
Marrow Transplant Program University of Minnesota
Over the last 20 years, umbilical cord blood(UCB) has become an
increasingly used source of hematopoeitic stem cells for transplan-
tation. For pediatric patients, UCB is now routinely utilized as a
source of stem cells. However, the median age of presentation of
most hematologic malignancies is in the 5th and 6th decades of life,
a time when other co-morbidities are more likely. Also, patients are
frequently referred to transplantation after extensive prior therapy,
including prior autologous transplantation. Nonmyeloablative
transplantation is particularly suitable for older patients and those
with other signiﬁcant clinical problems. The nonmyeloablative
conditioning regimens utilize drugs that are potently immunosup-
pressive with less toxicity and shortened periods of neutropenia.
The utilization of UCB as a source of stem cells for non myeloa-
blative transplantation was based on the hypothesis that despite less
alloreactivity, UCB would have enough T cells to mediate engraft-
ment. Several groups have now reported results with nonmyeloa-
blative UCB transplantation. The conditioning regimen has varied
signiﬁcantly; however, most institutions have included ﬂudarabine
and TBI. Among the series reported the median age of patients at
transplantation has ranged from 47 to 59 years, and the median
time to neutrophil recovery ranged between 12 and 21 days, with
an incidence of graft failure between 13% to 16%. The variation
on the time to neutrophil recovery largely reﬂects differences in
the intensity of the conditioning regimen. Despite the fact that the
best nonmyeloablative conditioning regimen for UCB transplan-
tation is not yet established, a recent study by Rocha et al. suggests
the combination of cyclophosphamide, ﬂudarabine and total body
irradiation may be superior to other regimens, with an incidence of
sustained donor engraftment of approximately 90%, as compared
to 65% with other regimens. The reported incidences of acute
graft-versus-host disease have ranged between 21% and 63%, and
chronic graft-versus-host disease 12% and 50%. Treatment related
mortality has been remarkably low, ranging from 18% to 27%.
Overall survival has been 33% to 44%. The University of Minne-
sota has the largest single center experience with nonmyeloabla-
tive UCB transplantation. The Minneapolis conditioning regi-
men consists of cyclophosphamide 50mg/kg, ﬂudarabine
200mg/m2 and a single dose of TBI 200cGy. The posttrans-
plantation immunosuppression is cyclosporine A and mycophe-
nolate mofetil. For patients who have not received intensive
chemotherapy in the 3 months prior to transplantation, anti-
thymocyte globulin was added to the conditioing regimen. If a
single unit is not large enough to be used as a graft, patients are
eligible to receive two partially HLA matched UCB units. UCB
unit grafts are at least 4/6 HLA matched to the recipent (HLA-A
and B at the antigen level, and DRBI at the allele level). In the
case of double unit grafts, units are at least 4/6 HLA matched to
the recipient and to each other, not necessarily at the same loci.
The median infused nucleated cell dose is 3.3  107/kg recip-
ients of one unit, compared to 3.7  107/kg for recipients of two
units. With 161 patients, primary neutrophil recovery is ob-
served in 94% with sustained donor engraftment in 87%. There
is no signiﬁcant difference between recipients of one or two
UCB units. Treatment related mortality is 25% at 3 years. The
incidence of Grade II-graft-versus-host disease is 54% and
grade III-IV 18%. Progression-free survival is 38% at 5 years
with a trend towards better progression-free survival for recip-
ients of 2 UCB units. Overall survival is 45% at 5 years, with no
signiﬁcant difference for recipients of one or two UCB units. In
multivariate analysis, disease’s status at transplantation and the
presence of clinical high-risk features were the two factors
correlated with higher risk of treatment related mortality,
poorer event-free survival and overall survival. In conclusion, a
growing body of evidence suggests that UCB is a safe and
efﬁcacious source of stem cells in the setting of myeloablative
transplantation. Patients who need non myeloabalative trans-
plant and who do not have a suitable sibling or unrelated donor
should be considered for UCB transplantation. Larger numbers
of patients will help further determine the role of UCB trans-
plantation in older patients and those with pre-exising co-
morbidities.
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DOUBLE REDUCED INTENSITY CORD BLOOD TRANSPLANTS IN ADULTS
Karen K. Ballen, Corey Cutler, Beow Y. Yeap, Steven L. McAfee,
Bimalangshu R. Dey, Eyal C. Attar, Richard L. Haspel, Deborah Liney,
John Koreth, Vincent Ho, Edwin P. Alyea, Robert J. Soiffer, Thomas R.
Spitzer, and Joseph H. Antin Massachusetts General Hospital and Dana
Farber Cancer Institute, Boston, MA
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Umbilical cord blood is a useful stem cell source for patients
without matched donors, but the low cell dose in individual cord
blood units has limited success in adults. We treated 43 patients
using a reduced intensity conditioning regimen of ﬂudarabine 30
mg/m2/day Days –8 through –3 (total dose 180 mg/m2), melpha-
lan 100 mg/m2 Day –2 and rabbit antithymocyte globulin 1.5
mg/kg Days –7,5,3,1 (total dose 6 mg/kg). Cord blood units
were a 4/6 or higher HLA A, B, DR allele match with the patient
and each other and achieved a minimum precryopreservation cell
dose of 3.7 10 (7) NC/kg. Twenty-one patients received GVHD
prophylaxis with cyclosporine and mycophenolate mofetil and 22
patients received tacrolimus and sirolimus. Median age was 49
years and majority of patients had acute leukemia or relapsed
lymphoma. The median days to neutrophil and platelet engraft-
ment were 20 and 41 days respectively for the cyclosporine/MMF
group and 21 days and 47 days for the tacrolimus/sirolimus pa-
tients. The incidence of acute GVHD Grades II-IV and chronic
GVHD in the cyclosporine/MMF group was 40% and 34% re-
spectively and 14% and 20% respectively for the tacrolimus/siroli-
mus patients. Transplant related mortality was 14% in both
groups. Overall survival and disease free survival were 57% and
57% at 2 years respectively for the cyclosporine/MMF patients and
73% and 51% at one year for the tacrolimus/sirolimus patients. In
a multivariate analysis, age greater than 50 was the only signiﬁcant
predictor of poorer survival. Chimerism studies revealed that one
cord unit predominates in 73% of patients. Predictors of the
predominant unit include ﬁrst infusion and higher CD34 and
nucleated cell counts. Double cord blood transplantation can be
performed safely with this reduced intensity regimen; the graft vs
leukemia effect is preserved despite a low rate of graft versus host
disease.
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INFECTION AND IMMUNE RECONSTITUTION AFTER HSCT: CHAL-
LENGES AND OPPORTUNITIES
Bruce R. Blazar University of Minnesota, MN
Post-BMT immune deﬁciency causes signiﬁcant morbidity and
mortality especially in allotransplant recipients. Despite hemato-
poietic engraftment and recovery of marrow function, recipients
have prolonged defects in generation of functional T and B lym-
phocytes. The clinical signiﬁcance has become evident in studies
utilizing high doses of pre-BMT cytotoxic therapy, donor hema-
topoietic stem cell (HSC) sources depleted of mature T lympho-
cytes, HLA-mismatched donors, and the use of potent lymphocyte
depleting antibodies. Most recipients of T-cell replete matched
sibling or unrelated donor HSC grafts experience late post-BMT
infections, the majority of which are viral and fungal, consistent
with T and B cell lymphopenia and dysfunction. A major cause of
post-BMT immune deﬁciency is the loss of thymopoietic capacity,
and impaired T cell recovery as a result of factors such as age,
radiation or graft-versus-host-disease (GVHD). Normal thymo-
poiesis depends on the interaction of the thymic stroma-derived
receptors and ligands. Damage to thymic epithelial cells by pre-
BMT conditioning impairs the ability of the thymus to generate
mature T lymphocytes after BMT. Approaches to lessen the injury
or hasten the repair of or replace thymic epithelial cell or stromal
elements or their products represent a promising strategy to speed
peripheral T cell reconstitution and function. Common lymphoid
progenitor cells (CLPs) migrate to the thymus where they receive
cues for development into mature thymocytes through a series of
deﬁned maturation steps that are time-dependent. Approaches to
increase the total number or homing of CLPs to the thymus or
alternatively to begin the thymic maturation process ex vivo may
shorten the time to peripheral T cell recovery. Such approaches
may result in extrathymic T cell maturation as well. B cell deﬁ-
ciency post-BMT can be prolonged, especially with injuries such as
GVHD and conditioning regimens that affect stromal cells and
secondary lymphoid organ architecture.
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MULTIVARIATE ANALYSIS OF PATIENT AND GRAFT SPECIFIC FACTORS
AMONG 330 RECIPIENTS OF UNRELATED CORD BLOOD TRANSPLANT
(UCBT) TO PREDICT RISK OF DEATH FROM OPPORTUNISTIC INFEC-
TIONS (OI) IN THE FIRST 6 MONTHS AFTER UCBT
Paul Szabolcs, MD Duke University, Durham, NC
Over the past 5 years we have studied the reconstitution of
immunity in the immediate post-UCBT period in 200 pediatric
recipients of single unit UCB at Duke University to identify sur-
rogate laboratory markers for those at risk for OI.
Several graft and patient-speciﬁc variables were also identiﬁed
as signiﬁcant factors when the laboratory measurements of den-
dritic and T cell reconstitution were analyzed. The overwhelm-
ing majority of OI related death occurs in the ﬁrst 6 months
after UCBT. To determine the impact of patient and graft-
speciﬁc factors on 6-month post-UCBT OI-related mortality
we reviewed all consecutive pediatric UCB recipients trans-
planted at Duke between June 1999 and Oct. 2005. Three
hundred thirty (330) pediatric recipients of single UCB grafts
were identiﬁed. Those receiving a second transplant for primary
graft failure were not analyzed. Two hundred twenty (220) of
the 330 patients (67%) were alive at 6 months. Of the 110
children who died by 6 months, 64 patients (58%) were identi-
ﬁed with OI (viral, fungal, protozoal infections) implicated as a
cause of death. The 46 patients who died prior to 6 months and
for whom OI was not implicated as a cause of death were
omitted from the study dataset, resulting in 284 patients. Of
these 284 patients, 220 patients (77%) were alive at 6 months
and 64 (23%) died at or before 6 months with cause of death
related to OI. Twenty two (22) patients died related to adeno-
virus infection and twelve (12) due to CMV infection, rendering
these two viruses the cause in 50% of all OI related deaths. A
logistic regression model was used to investigate the impact of
ten demographic and clinical characteristics on the risk of death
due to OI by 6 months post UCBT. These potential predictors
were gender, race, age at UCBT, CMV serology, HLA mis-
matches, malignancy, total body irradiation, total graft cell
dose/kg, CD34 graft cell dose/kg and CD3 graft cell dose/
kg, In univariate analyses, gender (p0.28), race (0.12) and TBI
(p0.80) did not predict 6-month death due to OI. Malignancy
(p0.07) was marginally associated with a greater probability of
6-month death due to OI. Malignancy without TBI was also
associated with a marginally higher probability of 6-month
death due to OI (p0.04). A signiﬁcantly greater probability of
6-month OI-related death was associated with CMV positive
serology (p0.0001), greater HLA mismatch (p0.006), and older
age (p0.0009). Higher total graft cell dose (p0.001), CD34
cell dose (p0.014) and CD3 cell dose (0.014) were associated
with lower probability of death due to OI at 6 months. Since
treatment with TBI was closely related to age two multivariable
models were ﬁt. Model 1 included; CMV (p0.0004), HLA
mismatch (p0.042) and Age (p0.03). Model 2 included;
CMV (p0.0001), HLA mismatch (p0.005) and malignancy
without TBI (p0.04). Since total graft cell dose, CD34 cell
dose and CD3 cell dose were also highly correlated, each of
these variables was introduced into models 1) and 2) separately.
Total graft cell dose was the strongest predictor when cell dose
variables were added to Models 1 (p0.0097) and 2 (p0.004).
CD34 cell dose contributed less signiﬁcantly to both models
(p0.02 for both models) while CD3 cell dose was signiﬁcant
in Model 2 only (p0.05). In Model 1 total graft cell dose and
CD34 cell dose replaced age because cell dose/kg inversely
correlates with age. The percent concordance among these
models ranged from 71-75%. Thus, in the pediatric cohort
6-month death due to OI can be predicted by the following risk
factors: older age, positive CMV serology, 1 HLA mismatch,
malignancy without TBI, and lower graft cell dose (total,
CD34 and CD3). In contrast, gender, race and TBI alone do
not predict 6-month death due to OI.
1399
